Clinical Trials Logo

HER-2 clinical trials

View clinical trials related to HER-2.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01542437 Completed - Clinical trials for Non-Small Cell Lung Cancer

Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer

NSCLC
Start date: January 2012
Phase: Phase 2
Study type: Interventional

Patients with stage IIIB and IV lung adenocarcinoma and progression to first-line chemotherapy were enrolled to receive afatinib 40 mg/day. Mutational EGFR and HER-2 status were assessed by RT-PCR. HER2 amplification was evaluated by FISH. Plasma HGF levels were measured by ELISA before and 2 months (mo) after the start of treatment. We assessed changes in serum HGF levels and their association with objective response rate (ORR), PFS and overall survival (OS).

NCT ID: NCT00897299 Completed - Breast Cancer Clinical Trials

Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With Chemotherapy

Start date: October 7, 2005
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict whether cancer will come back after treatment. PURPOSE: This laboratory study is identifying genes that may help predict recurrence in women with breast cancer treated with chemotherapy.